Smokers' metabolisms may suggest which quitting aid is best for them
There are a range of products aimed at helping smokers quit, but how can doctors predict with any accuracy which strategy will be the most helpful for an individual? A new study suggests that patients' metabolisms may provide clues to how successful different cessation aids may be.
Although smoking rates have fallen considerably in the US since the 1960s, when smoking was at its peak, there are currently 42 million Americans who smoke - including teenagers and young adults.
About 6 million people die every year from smoking-related diseases worldwide. Globally, $200 billion is spent annually on tobacco-related health care costs. What is more, nearly 70% of smokers who attempt to quit fail within their first week. As such, there is a great demand for scientists to provide suggestions for improved cessation treatments.
Some studies have previously investigated the relationship between metabolism and smoking cessation treatments. However, the metabolisms of participants were not tested before the participants were randomly assigned to treatments in these studies. Also, none of the previous studies investigated varenicline - a newer cessation medication.
The new study is a multi-center collaboration by researchers from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, the Centre for Addiction and Health at the University of Toronto, Canada, the State University of New York at Buffalo, NY, and The University of Texas MD Anderson Cancer Center in Houston.
The findings of the study - purported to be the first of its kind - are published in The Lancet Respiratory Medicine.
Across the four medical centers, researchers recruited a total of 1,246 treatment-seeking smokers. Testing the metabolisms of the participants, the researchers sorted the participants into two groups - 662 people were "slow metabolizers" and 584 people were considered to be "normal metabolizers."
Smokers' metabolisms may suggest which quitting aid is best for them
There are a range of products aimed at helping smokers quit, but how can doctors predict with any accuracy which strategy will be the most helpful for an individual? A new study suggests that patients' metabolisms may provide clues to how successful different cessation aids may be.
Although smoking rates have fallen considerably in the US since the 1960s, when smoking was at its peak, there are currently 42 million Americans who smoke - including teenagers and young adults.
About 6 million people die every year from smoking-related diseases worldwide. Globally, $200 billion is spent annually on tobacco-related health care costs. What is more, nearly 70% of smokers who attempt to quit fail within their first week. As such, there is a great demand for scientists to provide suggestions for improved cessation treatments.
Some studies have previously investigated the relationship between metabolism and smoking cessation treatments. However, the metabolisms of participants were not tested before the participants were randomly assigned to treatments in these studies. Also, none of the previous studies investigated varenicline - a newer cessation medication.
The new study is a multi-center collaboration by researchers from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, the Centre for Addiction and Health at the University of Toronto, Canada, the State University of New York at Buffalo, NY, and The University of Texas MD Anderson Cancer Center in Houston.
The findings of the study - purported to be the first of its kind - are published in The Lancet Respiratory Medicine.
Across the four medical centers, researchers recruited a total of 1,246 treatment-seeking smokers. Testing the metabolisms of the participants, the researchers sorted the participants into two groups - 662 people were "slow metabolizers" and 584 people were considered to be "normal metabolizers."
การแปล กรุณารอสักครู่..